PPARγ-dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF)

International Journal of Cancer

Volumn 117, Issue 6, 2005, Pages 923-933

  Cimini, AnnaMaria ^a   Cristiano, Loredana ^a   Colafarina, Sabrina ^a   Benedetti, Elisabetta ^a   Di Loreto, Silvia ^b   Festuccia, Claudio ^c   Amicarelli, Fernanda ^a   Canuto, Rosa Angela ^d   Cerù, Maria Paola ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b Institute of Transplant of Organs and Immunocytology   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Apoptosis; Cell proliferation; Fatty acids; Peroxisome proliferator activated receptors; Tumor cells

Indexed keywords

ANTINEOPLASTIC AGENT; CONJUGATED LINOLEIC ACID; GW 259662; GW 347845X; LINOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; BRAIN TUMOR; CANCER GRADING; CANCER INHIBITION; CANCER RECURRENCE; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIABETES MELLITUS; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIGAND BINDING; LIPID METABOLISM; METASTASIS INHIBITION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; CANCER INVASION; CELL ADHESION; CELL DIVISION; CELL MOTION; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOBLOTTING; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL DEATH; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HUMANS; IMMUNOBLOTTING; LINOLEIC ACIDS, CONJUGATED; NEOPLASM INVASIVENESS; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS);

EID: 28044446581     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21272     Document Type: Article

References (62)

1. Liu G, Bibus DM, Bode AM, Ma WY, Holman RT, Dong Z. Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and cell transformation in JB6 cells. Proc Natl Acad Sci USA 2001;98:7510-5.
2. Rao CV, Simi B, Hirose Y, Upadhyaya P, El-Bayoumy K, Reddy BS. Mechanisms in the chemoprevention of colon cancer: modulation of protein kinase C, tyrosine protein kinase and diacylglycerol kinase activities by 1,4-phenylenebis-(methylene)selenocyanate and impact of low-fat diet. Int J Oncol 2000;16:519-27.
3. Meterissian S, Kontogiannea M, Murty H, Gupta A. Omega-6 fatty acids can inhibit Fas-mediated apoptosis in a human colorectal carcinoma cell line: a potential mechanism for escape from immune surveillance. Int J Surg Invest 2000;2:253-7.
4. Sauer LA, Dauchy RT, Blask DE. Mechanism for the antitumor and anticachetic effects of n-3 fatty acids. Cancer Res 2000;60:5289-95.
5. Vartak S, McCaw R, Davis CS, Robbins ME, Spector AA. Gamma-linolenic acid (GLA) is cytotoxic to 36B10 malignant rat astrocytoma cells but not to normal rat astrocytes. Br J Cancer 1998;7:1612-20.
6. Xi S, Pham H, Ziboh WA. 15-hydroxyeicosatrienoic acid (15-HETrE) suppresses epidermal hyperproliferation via the modulation of nuclear transcription factor (AP-1) and apoptosis. Arch Dermatol Res 2000;292:397-403.
7. Ziboh VA, Miller CC, Cho Y. Metabolism of polyunsaturated fatty acids by skin epidermal enzymes: generation of antiinflammatory and antiproliferative metabolites. Am J Clin Nutr 2000;71:361S-6S.
8. Maggiora M, Bologna M, Cerù MP, Possati L, Angelucci A, Cimini A, Miglietta A, Bozzo F, Muzio G, Canuto RA. An overview on the effect of linoelic and conjugated linoleic acid on growth of several human tumour cell lines. Int J Cancer 2004;112:909-19.
9. Pariza MW, Park Y, Cook ME. Conjugated linoleic acid and the control of cancer and obesity. Toxicol Sci 1999;52(Suppl):107-10.
10. O'Shea M, Bassaganya-Riera J, Mohede IC. Immunomodulatory properties of conjugated linoleic acid. Am J Clin Nutr 2004;79:1199S-206S.
11. Field CJ, Schley PD. Evidence for potential mechanisms for the effect of conjugated linoleic acid on tumor metabolism and immune function: lessons from n-3 fatty acids. Am J Clin Nutr 2004;79:1190S-8S.
12. Moya-Camarena S, Vanden Heuvel JP, Blanchard SG, Leesnitzer LA, Belury MA. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARα. J Lipid Res 1999;40:1426-32.
13. Moya-Camarena S, Vanden Heuvel JP, Belury MA. Conjugated linoleic acid activates peroxisome proliferator-activated receptor α and β subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats. Biochim Biophys Acta 1999;1436:331-42.
14. McCarthy MF. Activation of PPARgamma may mediate a portion of the anticancer activity of conjugated linoliec acid. Med Hypotheses 2000;55:187-8.
15. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-50.
16. Kersten S, Wahli W. Peroxisome proliferator activated receptor agonists. Experientia 2000;89:141-51.
17. Khan SA, Vanden Heuvel JP. Role of nuclear receptors in the regulation of gene expression by dietary fatty acids. J Nutr Biochem 2003;14:554-67.
18. Gupta RA, Brockman JA, Sarraf P, Willson TM, DuBois RN. Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem 2001;276:29681-7.
19. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994;91:7355-9.
20. Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 2000;448:121-38.
21. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14.
22. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995;83:813-9.
23. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-deoxy-delta-12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995;83:803-12.
24. Bar-Tana J. Peroxisome proliferator-activated receptor gamma (PPAR-gamma) activation and its consequences in humans. Toxicol Lett 2001;120:9-19.
25. Theocharis S, Margeli A, Vielh P, Kouraklis G. Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. Cancer Treat Rev 2004;30:545-54.
26. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004;4:61-70.
27. Leibowitz SB, Kantoff PW. Differentiating agents and the treatment of prostate cancer: vitamin D3 and peroxisome proliferator-activated receptor gamma ligands. Semin Oncol 2003;30:698-708.
28. Kopelovich L, Fay JR, Glazer RI, Crowell JA. Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol Cancer Ther 2002;1:357-63.
29. Holland EC. Progenitor cells and glioma formation. Curr Opin Neurol 2001;14:683-8.
30. - T cells in murine tumors generated independent of antigen specificity. Immunology 2004;172:1602-11.
31. Moynihan T, Grossman S. The role of chemiotherapy in the treatment of primary tumors of the central nervous system. Cancer Invest 1994;12:88-97.
32. Cimini A, Cristiano L, Bernardo A, Farioli-Vecchioli S, Stefanini S, Cerù MP. Presence and inducibility of peroxisomes in a human glioblastoma cell line. Biochim Biophys Acta 2000;1474:397-409.
33. Chattopadhyay N, Singh D, Heese O, Godbole MM, Sinohara T, Balck PM, Brown E. Expression of peroxisome proliferator-activated receptors (PPARs) in human astrocytic cells: PPARγ agonists as inducers of apoptosis. J Neurosci 2000;61:67-74.
34. Nwankwo JO, Robbins ME. Peroxisome proliferator-activated receptor-gamma expression in human malignat brain, breast and prostate-derived cells. Prostaglandin Leukot Essent Fatty Acids 2001;64:241-5.
35. Liu KG, Lambert MH, Ayscue AH, Henke BR, Leesnitzer LM, Oliver WR Jr, Plunket KD, Xu HE, Sternbach DD, Willson TM. Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight. Bioorg Med Chem Lett 2001;11:3111-3.
36. Laemmli EK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
37. Nugent C, Prins JB, Whitehead JP, Savage D, Wentworth JM, Chatterjee VK, O'Rahilly S. Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation. Mol Endocrinol 2001;15:1729-38.
38. Ip C, Scimeca JA. Conjugated linoleic acid and linoleic acid are distinctive modulators of mammary carcinogenesis. Nutr Cancer 1997;27:131-5.
39. Kritchevsky D. Antimutagenic and some other effects of conjugated linoleic acid. Br J Nutr 2000;83:459-65.
40. Pariza MW, Park Y, Cook ME. Mechanism of action of conjugated linoleic acid: evidence and speculation. Proc Soc Exp Biol Med 2000;223:8-13.
41. Belury MA. Inhibition of carcinogenesis by conjugated linoleic acid: potential mechanisms of action. J Nutr 2002;132:2995-8.
42. Palombo JD, Granguly A, Bistrian BR, Menard MP. The antiproliferative effects of biologically active isomers of conjugated linoleic acid on human colorectal and prostatic cells. Cancer Lett 2002;177:163-72.
43. Schonberg SA, Krokan HE. The inhibitory effect of conjugated dienoic derivatives (CLA) of linoleic acid on the growth of human tumor cell lines is in part due to increased lipid peroxidation. Anticancer Res 1995;15:1241-6.
44. Schonberg SA, Rudra PK, Noding R, Skorpen F, Bjerve KS, Krokan HE. Evidence that changes in Se-glutathione peroxidase levels affect the sensitivity of human tuour cell lines to n-3 fatty acids. Carcinogenesis 1997;18:1897-904.
45. Cimini A, Brunori A, Candi E, Catani MV, Cerù MP. Catalase activity in neuroectodermal cell lines and tumors. Clin Chem Enzym Comms 1993;6:63-7.
46. Amicarelli F, Colafarina S, Cattani F, Cimini A, Di Ilio C, Cerù MP, Miranda M. Scavenging systems efficiency is crucial for cell resistance to ROS-mediated methylglyoxal injury. Free Radical Biol Med 2003;35:856-71.
47. Bassaganya-Riera J, Hontecillas R, Beitz DC. Colonic anti-inflammatory mechanisms of conjugated linoleic acid. Clin Nutr 2002;21:451-9.
48. Winnett G, van Hagen D, Schrey M. Prostaglandin J2 metabolites inhibit aromatase activity by redox-sensitive mechanisms: potential implications for breast cancer therapy. Int J Cancer 2003;103:600-5.
49. Takamura T, Nohara E, Nagai Y, Kobayashi K. Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPAR-gamma mRNA expression in 3T3-L1 adipocytes. Eur J Pharmacol 2001;422:23-9.
50. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 1997;94:237-41.
51. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998;1:465-70.
52. Zander T, Kraus JA, Grommes C, Schlegel U, Feinstein D, Klockgether T, Landreth G, Koenigsknecht J, Heneka MT. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem 2002;81:1052-60.
53. Asano K, Kubo O, Tajika Y, Takakura K, Suzuki S. Expression of cadherin and CSF dissemination in malignant astrocytic tumors. Neurosurg Rev 2002;23:39-44.
54. Perego C, Vanoni C, Massari S, Raimondi A, Pola S, Cattaneo MG, Francolini M, Vicentini LM, Pietrini G. Invasive behaviour of glioblastoma cell lines is associated with altered organisation of the cadherin-catenin adhesion system. J Cell Sci 2002;115:3331-40.
55. Worley JR, Baugh MD, Hughes DA, Edwards DR, Hogan A, Sampson MJ, Gavrilovic J. Metalloproteinase expression in PMA-stimulated THP-1 cells: effects of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists and 9-cis-retinoic acid. J Biol Chem 2003;278:51340-6.
56. Nishida E, Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci 1993;18:128-31.
57. Marshall JC. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 1994;4:82-9.
58. Krueger JS, Keshamouni VG, Atanaskova N, Reddy KB. Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 2001;20:4209-18.
59. Keshamouni VG, Mattingly RR, Reddy KB. Mechanism of 17-beta-estradiol- induced Erk1/2 activation in breast cancer cells: a role for HER2 AND PKC-delta. J Biol Chem 2002;277:22558-65.
60. Sivaraman VS, Wang H, Nouvo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997;99:1478-83.
61. Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol 1998;153:1411-23.
62. Spector R. Fatty acid transport through the blood brain barrier. J Neurochem 1988;50:639-43.